Enzyme-linked immunospot assay for detection of human respiratory syncytial virus F protein-specific gamma interferon-producing T cells

Clinical and Vaccine Immunology

Volumn 21, Issue 5, 2014, Pages 628-635

  Patton, Kathryn ^a   Aslam, Shahin ^a   Lin, Jim ^a   Yu, Li ^a   Lambert, Stacie ^a   Dawes, Glenn ^a,c   Esser, Mark T ^a   Woo, Jennifer ^a,d   Janetzki, Sylvia ^b   Cherukuri, Anu ^a,e  

^a MEDIMMUNE   (United States)

^b ZellNet Consulting Inc   (United States)

^c STANFORD UNIVERSITY   (United States)

^d Immune Design Corp   (United States)

^e BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS PROTEIN F; F PROTEIN, HUMAN RESPIRATORY SYNCYTIAL VIRUS; VIRUS FUSION PROTEIN;

ADULT; AGED; ANALYTIC METHOD; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL VIABILITY; CONTROLLED STUDY; CRYOPRESERVATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; INCUBATION TIME; LIMIT OF DETECTION; LIMIT OF QUANTITATION; LYMPHOCYTE COUNT; MALE; MEMORY T LYMPHOCYTE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; QUALITATIVE RESEARCH; QUANTITATIVE STUDY; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; VIRUS DETECTION; CELL CULTURE; EVALUATION STUDY; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MONONUCLEAR CELL; PRESERVATION; PROCEDURES; REPRODUCIBILITY; SECRETION (PROCESS); T LYMPHOCYTE; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; CELLS, CULTURED; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; HUMANS; IMMUNOLOGIC MEMORY; INTERFERON-GAMMA; LEUKOCYTES, MONONUCLEAR; MALE; PRESERVATION, BIOLOGICAL; REPRODUCIBILITY OF RESULTS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SENSITIVITY AND SPECIFICITY; T-LYMPHOCYTES; VIRAL FUSION PROTEINS; YOUNG ADULT;

EID: 84899718545     PISSN: 15566811     EISSN: 1556679X     Source Type: Journal    
DOI: 10.1128/CVI.00736-13     Document Type: Article

References (31)

1. Kostense S, Hendriks J. 2012. Challenges of immunogenicity assays for vaccines. Bioanalysis 4:397-406. http://dx.doi.org/10.4155/bio.11.327.
2. Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, Anderson K, Collins KB, Gaunt C, Fernandez VR, Zhu L, Kierstead L, Thaler S, Gupta SB, Straus W, Mehrotra D, Tobery TW, Casimiro DR, Shiver JW. 2007. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J. Acquir. Immune Defic. Syndr. 45:20-27. http://dx.doi.org/10.1097/QAI. 0b013e3180377b5b. (Pubitemid 46684439)
3. Levin MJ, Oxman MN, Zhang JH, Johnson GR, Stanley H, Hayward AR, Caulfield MJ, Irwin MR, Smith JG, Clair J, Chan IS, Williams H, Harbecke R, Marchese R, Straus SE, Gershon A, Weinberg A. 2008. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J. Infect. Dis. 197:825-835. http://dx.doi.org/10.1086/528696. (Pubitemid 351417005)
4. Tyring SK, Stek JE, Smith JG, Xu J, Pagnoni M, Chan IS, Silber JL, Parrino J, Levin MJ. 2012. Varicella-zoster virus-specific enzyme-linked immunospot assay responses and zoster-associated pain in herpes zoster subjects. Clin. Vaccine Immunol. 19:1411-1415. http://dx.doi.org/10.1128/CVI.00095-12.
5. Schanzer DL, Langley JM, Tam TW. 2008. Role of influenza and other respiratory viruses in admissions of adults to Canadian hospitals. Influenza Other Respir. Viruses 2:1-8. http://dx.doi.org/10.1111/j.1750-2659.2008.00035.x.
6. Murata Y, Falsey AR. 2007. Respiratory syncytial virus infection in adults. Antivir. Ther. 12: 659 - 670. http://dx.doi.org/10.1097/MCP. 0b013e3282f79651.
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951. (Pubitemid 40570923)
8. Olson MR, Varga SM. 2008. Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus. Expert Rev. Vaccines 7:1239-1255. http://dx.doi.org/10.1586/14760584.7.8.1239.
9. Walsh EE, Peterson DR, Falsey AR. 2004. Risk factors for severe respiratory syncytial virus infection in elderly persons. J. Infect. Dis. 189:233-238. http://dx.doi.org/10.1086/380907. (Pubitemid 38147246)
10. Cusi MG, Martorelli B, Di Genova G, Terrosi C, Campoccia G, Correale P. 2010. Age related changes in T cell mediated immune response and effector memory to Respiratory Syncytial Virus (RSV) in healthy subjects. Immun. Ageing 7:14. http://dx.doi.org/10.1186/1742-4933-7-14.
11. Looney RJ, Falsey AR, Walsh E, Campbell D. 2002. Effect of aging on cytokine production in response to respiratory syncytial virus infection. J. Infect. Dis. 185:682-685. http://dx.doi.org/10.1086/339008. (Pubitemid 34171474)
12. Cherukuri A, Patton K, Gasser RA, Jr, Zuo F, Woo J, Esser MT, Tang RS. 2013. Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein. Clin. Vaccine Immunol. 20:239-247. http://dx.doi.org/10.1128/CVI.00580-12.
13. Falsey AR, Walsh EE, Capellan J, Gravenstein S, Zambon M, Yau E, Gorse GJ, Edelman R, Hayden FG, McElhaney JE, Neuzil KM, Nichol KL, Simoes EA, Wright PF, Sales VM. 2008. Comparison of the safety and immunogenicity of 2 respiratory syncytial virus (rsv) vaccines - nonadjuvanted vaccine or vaccine adjuvanted with alum - given concomitantly with influenza vaccine to high-risk elderly individuals. J. Infect. Dis. 198:1317-1326. http://dx.doi.org/10.1086/592168.
14. Kurzweil V, Tang R, Galinski M, Wang K, Zuo F, Cherukuri A, Gasser RA, Jr, Malkin E, Sifakis F, Mendel DB, Esser MT. 2013. Translational sciences approach to RSV vaccine development. Expert Rev. Vaccines 12:1047-1060. http://dx.doi.org/10.1586/14760584.2013.824706.
15. Maecker HT, Dunn HS, Suni MA, Khatamzas E, Pitcher CJ, Bunde T, Persaud N, Trigona W, Fu TM, Sinclair E, Bredt BM, McCune JM, Maino VC, Kern F, Picker LJ. 2001. Use of overlapping peptide mixtures as antigens for cytokine flow cytometry. J. Immunol. Methods 255:27-40. http://dx.doi.org/10.1016/S0022- 1759(01)00416-1.
16. Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. 2012. T cell assays and MIATA: the essential minimum for maximum impact. Immunity 37:1-2. http://dx.doi.org/10. 1016/j.immuni.2012.07.010.
17. Tang RS, MacPhail M, Schickli JH, Kaur J, Robinson CL, Lawlor HA, Guzzetta JM, Spaete RR, Haller AA. 2004. Parainfluenza virus type 3 expressing the native or soluble fusion (F) protein of respiratory syncytial virus (RSV) confers protection from RSV infection in African green monkeys. J. Virol. 78:11198-11207. http://dx.doi.org/10.1128/JVI.78.20.11198-11207.2004. (Pubitemid 39299659)
18. Searle SR, Casella G, McCulloch CE. 1992. Variance components. John Wiley & Sons, New York, NY.
19. Walsh PN, Friedrich DP, Williams JA, Smith RJ, Stewart TL, Carter DK, Liao HX, McElrath MJ, Frahm N. 2013. Optimization and qualification of a memory B-cell ELISpot for the detection of vaccine-induced memory responses in HIV vaccine trials. J. Immunol. Methods 394:84-93. http://dx.doi.org/10.1016/j.jim. 2013.05.007.
20. Smith JG, Joseph HR, Green T, Field JA, Wooters M, Kaufhold RM, Antonello J, Caulfield MJ. 2007. Establishing acceptance criteria for cell-mediated-immunity assays using frozen peripheral blood mononuclear cells stored under optimal and suboptimal conditions. Clin. Vaccine Immunol. 14:527-537. http://dx.doi.org/10.1128/CVI.00435-06.
21. Mallone R, Mannering SI, Brooks-Worrell BM, Durinovic-Bello I, Cilio CM, Wong FS, Schloot NC. 2011. Isolation and preservation of peripheral blood mononuclear cells for analysis of islet antigen-reactive T cell responses: position statement of the T-Cell Workshop Committee of the Immunology of Diabetes Society. Clin. Exp. Immunol. 163:33-49. http://dx.doi.org/10.1111/j. 1365-2249.2010.04272.x.
22. Bull M, Lee D, Stucky J, Chiu YL, Rubin A, Horton H, McElrath MJ. 2007. Defining blood processing parameters for optimal detection of cryopreserved antigen-specific responses for HIV vaccine trials. J. Immunol. Methods 322:57-69. http://dx.doi.org/10.1016/j.jim.2007.02.003. (Pubitemid 46560582)
23. Germann A, Schulz JC, Kemp-Kamke B, Zimmermann H, von Briesen H. 2011. Standardized serum-free cryomedia maintain peripheral blood mononuclear cell viability, recovery, and antigen-specific T-cell response compared to fetal calf serum-based medium. Biopreserv. Biobank. 9:229-236. http://dx.doi.org/10.1089/ bio.2010.0033.
24. Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A. 2010. Performance of serum-supplemented and serum-free media in IFNgamma Elispot assays for human T cells. Cancer Immunol. Immunother. 59:609-618. http://dx.doi.org/10.1007/s00262-009-0788-2.
25. Weinberg A, Song LY, Wilkening CL, Fenton T, Hural J, Louzao R, Ferrari G, Etter PE, Berrong M, Canniff JD, Carter D, Defawe OD, Garcia A, Garrelts TL, Gelman R, Lambrecht LK, Pahwa S, Pilakka-Kanthikeel S, Shugarts DL, Tustin NB. 2010. Optimization of storage and shipment of cryopreserved peripheral blood mononuclear cells from HIV-infected and uninfected individuals for ELISPOT assays. J. Immunol. Methods 363:42-50. http://dx.doi.org/10.1016/j.jim.2010.09. 032.
26. Mander A, Gouttefangeas C, Ottensmeier C, Welters MJ, Low L, van der Burg SH, Britten CM. 2010. Serum is not required for ex vivo IFN-gamma ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program. Cancer Immunol. Immunother. 59:619-627. http://dx.doi.org/10.1007/ s00262-009-0814-4.
27. Deng Y, Jing Y, Campbell AE, Gravenstein S. 2004. Age-related impaired type 1 T cell responses to influenza: reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 172:3437-3446. (Pubitemid 38337923)
28. Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, Pawelec G. 2008. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. Immun. Ageing 5:6. http://dx.doi.org/10.1186/1742-4933-5-6.
29. Janetzki S, Britten CM. 2012. The impact of harmonization on ELISPOT assay performance. Methods Mol. Biol. 792:25-36. http://dx.doi.org/10.1007/978- 1-61779-325-7-2.
30. Kelley M. 2008. Considerations while setting up cell-based assays, p 1-9. In Prabhakar U, KelleyM(ed), Validation of cell-based assays in the GLP setting: a practical guide. John Wiley & Sons, Ltd., Chichester, United Kingdom. http://dx.doi.org/10.1002/9780470987810.
31. van der Burg SH. 2008. Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding. Expert Rev. Vaccines 7:1-5. http://dx.doi.org/10.1586/14760584.7.1.1.